Last $61.85 USD
Change Today -1.25 / -1.98%
Volume 6.9M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 8:04 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$63.44
Previous Close
$63.10
Day High
$63.56
Day Low
$61.69
52 Week High
12/8/14 - $70.76
52 Week Low
04/11/14 - $45.50
Market Cap
98.6B
Average Volume 10 Days
7.8M
EPS TTM
$3.03
Shares Outstanding
1.6B
EX-Date
01/13/15
P/E TM
20.4x
Dividend
$1.96
Dividend Yield
2.83%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 11/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Opens AbbVie Innovation Center Opens at the University of Illinois-Urbana Research Park

AbbVie has opened the AbbVie Innovation Center on campus at the University of Illinois Research Park in Urbana-Champaign. The AbbVie Innovation Center plans to employ more than 18 students, from undergraduate to graduate level, on a part-time basis throughout the year. Eight students have started working on several AbbVie Research & Development Information Technology projects, which is the initial focus of work in the AbbVie Innovation Center. AbbVie is currently hiring for several open positions.

AbbVie Inc. Announces Quarterly Dividend

AbbVie Inc. announced that its quarterly dividend will be increased to $0.49 per share, an increase of nearly 17%, beginning with a dividend payable next month.

AbbVie Receives U.S. FDA Approval of DUOPA (Carbidopa and Levodopa) Enteral Suspension

The U.S. Food and Drug Administration (FDA) has approved AbbVie's DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S. In the advanced stages of Parkinson's disease, patients may begin to experience 'off' time, or periods of poor mobility, slowness and stiffness. Additionally, in Parkinson's disease patients, the spontaneous emptying of the stomach becomes delayed and unpredictable, which can affect the timing of when orally administered medicines leave the stomach and are absorbed in the small intestine. DUOPA provides patients with the same active ingredients as orally-administered carbidopa and levodopa immediate release, but is delivered in a suspension that goes directly into the small intestine via a tube placed by a percutaneous endoscopic gastrostomy procedure with jejunal extension (PEG-J). This type of administration is intended to bypass the stomach.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $61.85 USD -1.25

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $154.64 USD -4.25
AstraZeneca PLC 4,740 GBp -4.00
Bristol-Myers Squibb Co $61.33 USD -0.66
Eli Lilly & Co $70.97 USD -0.76
Novo Nordisk A/S kr301.00 DKK +2.60
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 27.5x
Price/Sales 5.1x
Price/Book 21.6x
Price/Cash Flow 27.1x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.